313 related articles for article (PubMed ID: 32134464)
21. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Danese MD; Reyes C; Northridge K; Lubeck D; Lin CY; O'Connor P
Clin Ther; 2008 Apr; 30(4):775-84. PubMed ID: 18498925
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of adjuvant FOLFOX vs 5FU/LV in adults over age 65 with stage II and III colon cancer using a novel hybrid approach.
Lund JL; Webster-Clark MA; Hinton SP; Shmuel S; Stürmer T; Sanoff HK
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1579-1587. PubMed ID: 33015888
[TBL] [Abstract][Full Text] [Related]
23. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
24. Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
Mack CD; Carpenter W; Meyer AM; Sanoff H; Stürmer T
Cancer; 2012 Jun; 118(11):2925-34. PubMed ID: 22072441
[TBL] [Abstract][Full Text] [Related]
25. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study.
Yeh JM; Tramontano AC; Hur C; Schrag D
Gastric Cancer; 2017 Sep; 20(5):811-824. PubMed ID: 28205057
[TBL] [Abstract][Full Text] [Related]
27. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis.
Furuse J; Gemma A; Ichikawa W; Okusaka T; Seki A; Ishii T
Jpn J Clin Oncol; 2017 Sep; 47(9):832-839. PubMed ID: 28541474
[TBL] [Abstract][Full Text] [Related]
28. Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.
Oberstein PE; Hershman DL; Khanna LG; Chabot JA; Insel BJ; Neugut AI
Cancer Invest; 2013 Jun; 31(5):316-22. PubMed ID: 23614655
[TBL] [Abstract][Full Text] [Related]
29. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
Sundararajan V; Mitra N; Jacobson JS; Grann VR; Heitjan DF; Neugut AI
Ann Intern Med; 2002 Mar; 136(5):349-57. PubMed ID: 11874307
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
[TBL] [Abstract][Full Text] [Related]
31. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
32. Effect of Incorporation of Pretreatment Serum Carcinoembryonic Antigen Levels Into AJCC Staging for Colon Cancer on 5-Year Survival.
Thirunavukarasu P; Talati C; Munjal S; Attwood K; Edge SB; Francescutti V
JAMA Surg; 2015 Aug; 150(8):747-755. PubMed ID: 26083632
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.
O'Connor ES; Greenblatt DY; LoConte NK; Gangnon RE; Liou JI; Heise CP; Smith MA
J Clin Oncol; 2011 Sep; 29(25):3381-8. PubMed ID: 21788561
[TBL] [Abstract][Full Text] [Related]
34. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).
Lamont EB; Schilsky RL; He Y; Muss H; Cohen HJ; Hurria A; Meilleur A; Kindler HL; Venook A; Lilenbaum R; Niell H; Goldberg RM; Joffe S;
J Natl Cancer Inst; 2015 Jan; 107(1):336. PubMed ID: 25432408
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis.
Shaib WL; Jones JS; Goodman M; Sarmiento JM; Maithel SK; Cardona K; Kane S; Wu C; Alese OB; El-Rayes BF
Oncologist; 2018 Jun; 23(6):704-711. PubMed ID: 29445028
[TBL] [Abstract][Full Text] [Related]
36. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Bickenbach KA; Gonen M; Tang LH; O'Reilly E; Goodman K; Brennan MF; D'Angelica MI; Dematteo RP; Fong Y; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2012 May; 19(5):1663-9. PubMed ID: 22130621
[TBL] [Abstract][Full Text] [Related]
37. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.
Neugut AI; Matasar M; Wang X; McBride R; Jacobson JS; Tsai WY; Grann VR; Hershman DL
J Clin Oncol; 2006 May; 24(15):2368-75. PubMed ID: 16618946
[TBL] [Abstract][Full Text] [Related]
38. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
Westphalen CB; Kukiolka T; Garlipp B; Hahn L; Fuchs M; Malfertheiner P; Reiser M; Kütting F; Heinemann V; Beringer A; Waldschmidt DT
BMC Cancer; 2020 Feb; 20(1):155. PubMed ID: 32093649
[TBL] [Abstract][Full Text] [Related]
39. Postoperative mortality following multi-modality therapy for pancreatic cancer: Analysis of the SEER-Medicare data.
Nayar P; Chandak A; Gupta N; Yu F; Qiu F; Ganti AK; Are C
J Surg Oncol; 2017 Feb; 115(2):158-163. PubMed ID: 28133817
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Bednar F; Zenati MS; Steve J; Winters S; Ocuin LM; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2017 May; 24(5):1406-1413. PubMed ID: 27896518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
